• NICE approves AstraZeneca’s COPD drug europeanpharmaceuticalreview
    July 04, 2017
    The National Institute for Health and Care Excellence (NICE) has published draft guidance recommending roflumilast (Daxas, AstraZeneca) for chronic obstructive pulmonary disease (COPD).
PharmaSources Customer Service